John W. Kozarich - Apr 24, 2024 Form 4 Insider Report for LIGAND PHARMACEUTICALS INC (LGND)

Role
Director
Signature
By: /s/ Andrew Reardon, Attorney-in-Fact For: John W. Kozarich
Stock symbol
LGND
Transactions as of
Apr 24, 2024
Transactions value $
$113,840
Form type
4
Date filed
4/26/2024, 06:35 PM
Previous filing
Jun 13, 2023
Next filing
Jun 18, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LGND Common Stock Options Exercise $114K +2.89K +7.3% $39.35 42.5K Apr 24, 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LGND Non-Qualified Stock Option (right to buy) Options Exercise $0 -2.89K -100% $0.00* 0 Apr 24, 2024 Common Stock 2.89K $39.35 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This Option was previously reported as a Grant of 3,312 shares, which vested in full on April 24, 2015, at an exercise price of $67.53 per share, but was adjusted pursuant to the OmniAb Inc. separation from the issuer.